News for Sanofi Stock (SNY)

Sanofi (SNY) Could Be a Great Choice

Zacks Investment Research • 06/21/23

2 Biopharma Stocks Making Big Moves Tuesday

The Motley Fool • 06/20/23

Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim

GlobeNewsWire • 06/20/23

Sanofi (SNY) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

Seeking Alpha • 06/14/23

Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients

GlobeNewsWire • 06/13/23

Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants

GlobeNewsWire • 06/08/23

US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy

Reuters • 06/08/23

FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection

Market Watch • 06/08/23

International Wide-Moat Stocks On Sale - The June 2023 Heat Map

Seeking Alpha • 06/08/23

The 7 Most Reliable Dividend Stocks to Buy Now

InvestorPlace • 06/06/23

US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy

Reuters • 06/06/23

Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan

GlobeNewsWire • 06/01/23

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

Zacks Investment Research • 05/31/23

Was This $3 Billion Deal a Wise Move for Sanofi?

The Motley Fool • 05/31/23

Sanofi announces positive data for frexalimab product to treat multiple sclerosis

Reuters • 05/31/23

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

GlobeNewsWire • 05/31/23

Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

GlobeNewsWire • 05/25/23

2 Bear Market Defying Stocks to Buy in May

The Motley Fool • 05/22/23

Sanofi: smoker's lung drug benefit was swift and sustained in trial

Reuters • 05/22/23

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

GlobeNewsWire • 05/21/23

Sanofi Wins Supreme Court Patent Dispute With Amgen

WSJ • 05/18/23

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi

PRNewsWire • 05/18/23

Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns

Investors Business Daily • 05/12/23

Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

GlobeNewsWire • 05/12/23

Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate

Market Watch • 05/11/23